

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Stacey Bolk, George Q. Daley and Jeanette J. McCarthy

Application No.: 10/007,781 Group Art Unit: 1645

Filed: November 13, 2001 Examiner: Not Assigned

Confirmation No.: 1826

Title: Association of Thrombospondin Polymorphisms with Vascular Disease

1645
#7
RECEIVED
JAN 22 2003
TECH CENTER 1600/2900

CERTIFICATE OF MAILING	
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, P.O. Box 2327, Arlington, VA 22202	
on <u>01/15/03</u>	<u>Kelley A. Foss</u>
Date	Signature
<u>Kelley A. Foss</u>	
Typed or printed name of person signing certificate	

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
P.O. Box 2327
Arlington, VA 22202

Sir:

This Information Disclosure Statement is submitted:

- ☐ under 37 CFR 1.129(a), or
(First/Second submission after Final Rejection)
- ☒ under 37 CFR 1.97(b), or
(Within any one of the following time periods: three months of filing national application (other than a CPA) or date of entry of the national stage in an international application; or before the mailing date of a first office action on the merits in a non-provisional application, including a CPA, or a Request for Continued Examination).
- ☐ under 37 CFR 1.97(c) together with either:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, or
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or
(After the 37 CFR 1.97(b) time period, but before final action or notice of allowance, whichever occurs first)
- ☐ under 37 CFR 1.97(d) together with:
- ☐ a Statement under 37 CFR 1.97(e), as checked below, and
- ☐ a \$180.00 fee under 37 CFR 1.17(p), or
(Filed after final action or notice of allowance, whichever occurs first, but on or before payment of the issue fee)
- ☐ under 37 CFR 1.97(i):
Applicant requests that the IDS and cited reference(s) be placed in the application filewrapper.
(Filed after payment of issue fee)

Statement Under 37 CFR 1.97(e)

- ☐ Each item of information contained in this Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned, after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

Statement Under 37 CFR 1.704(d) (Patent Term Adjustment)

Applies to original applications (other than design) filed on or after May 29, 2000

- ☐ Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and this communication was not received by any individual designated in § 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.
- ☒ Enclosed herewith is form PTO-1449:
- ☒ Copies of the cited references (AA, AB, AR-AT2) are enclosed.
- ☐ Copies of cited references are enclosed except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed. [The earlier application contains copies of the cited references.]
- ☐ The listed references were cited in the enclosed International Search Report in a counterpart foreign application.
- ☐ The "concise explanation" requirement (non-English references) for reference(s) [] under 37 CFR 1.98(a)(3) is satisfied by:
- ☐ the explanation provided on the attached sheet.
 - ☐ the explanation provided in the Specification.
 - ☐ submission of the enclosed International Search Report.
 - ☐ submission of the enclosed English-language version of a foreign Search Report and/or foreign Office Action.
 - ☐ the enclosed English language abstract.

[X] Applicants request that the following non-published pending applications be considered:

Examiner's
Initials

U.S. Patent Application No. 09/657,472, by Eric S. Lander, *et al.*, filed September 7, 2002, Docket No.: 2825.1027-001.

U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

U.S. Patent Application No. [], by [inventor(s)], filed [], Docket No.: []

Examiner

Date

[X] A copy of each above-cited application, including the current claims, is enclosed.

[] A copy of each above-cited application, including the current claims, is enclosed, except those entered in prior application, U.S. Application No. [], to which priority under 35 U.S.C. 120 is claimed.

The Examiner is requested to return a copy of the above list of pending applications indicating which references were considered with the next office communication.

It is requested that the information disclosed herein be made of record in this application.

Method of payment:

[] A check for the fee noted above is enclosed, or the fee has been included in the check with the accompanying Reply. A copy of this Statement is enclosed.

[] Please charge Deposit Account 08-0380 in the amount of \$[]. A copy of this Statement is enclosed.

[X] Please charge any deficiency in fees and credit any overpayment to Deposit Account 08-0380.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

By

Pamela A. Torpey
Pamela A. Torpey

Registration No.: 45,736

Telephone: (978) 341-0036

Facsimile: (978) 341-0136

Concord, MA 01742-9133

Dated:

January 15, 2003

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2825.2025-001		APPLICATION NO. 10/007,781	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION JAN 21 2003 January 15, 2003 (Use several sheets if necessary)		APPLICANT Stacey Bolk, et al.			
		FILING DATE November 13, 2001		CONFIRMATION NO. 1826	
RECEIVED JAN 22 2003 TECH CENTER 1600-2890					
U.S. PATENT DOCUMENTS					
EXAM- INER INI- TIAL		DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE		NAME
	AA	5,750,502	12 May 98		Jessell, et al.
	AB	5,279,966	18 Jan 94		Jessell, et al.
FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS
	AL				
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	AR	Polymeropoulos, M.H., et al., "Dinucleotide Repeat Polymorphism at the Human Thrombospondin Gene (THBS1)," <i>Nucleic Acids Research</i> , 18(24):7467 (1990).			
	AS	Wang, D.G., et al., "Large-Scale Identification, Mapping, and Genotyping of Single-Nucleotide Polymorphisms in the Human Genome," <i>Science</i> , 280:1077-1082 (1998).			
	AT	Fan, J., et al., "Genetic Mapping: Finding and Analyzing Single-Nucleotide Polymorphisms With High-Density DNA Arrays," <i>American Journal of Human Genetics</i> , 61 (4th suppl.):1601 (1997) (Abstract only).			
	AU	Tang, S., et al., "Enhancement of Endothelial Cell Migration and Angiogenesis In Vitro by a Novel Gene Product," <i>Circulation</i> , American Heart Association, Abstract No. 3821 from the 71 st Scientific Sessions, Dallas, Texas, (November 8-11, 1998).			
	AV	Kalka, C., et al., "Novel Genes Containing the Thrombospondin Type 1 Domain Suppress the Development of Angiogenesis in an in-vivo Model of Peripheral Vascular Ischemia," <i>Circulation</i> , American Heart Association, Abstract No. 3825 from the 71 st Scientific Sessions, Dallas, Texas, (November 8-11, 1998).			
	AW	Lange, L.A., et al., "Autosomal Genome-Wide Scan for Coronary Artery Calcification Loci in Sibships at High Risk for Hypertension," <i>Arterioscler. Thromb. Vasc. Biol.</i> , 22:418-423 (2002).			
	AX	Accession No. AF102887, <i>Mus musculus</i> Thrombospondin-4 mRNA, October 19, 1999.			
	AY	Accession No. X89963, <i>R. norvegicus</i> mRNA TSP-4 protein, January 29, 1998.			
	AZ	Accession No. Z19091, <i>X. laevis</i> encoding thrombospondin-4, June 22, 1993.			
EXAMINER			DATE CONSIDERED		

PTO-1449 REPRODUCED		ATTORNEY DOCKET NO. 2825.2025-001		APPLICATION NO. 10/007,781	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION January 15, 2003 (Use several sheets if necessary)		APPLICANT Stacey Bolk, et al.			
		FILING DATE November 13, 2001		CONFIRMATION NO. 1826	
U.S. PATENT DOCUMENTS					
EXAM- INER INI- TIAL		DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE		
FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)					
	AR2	Kyriakides, T.R., "Mice That Lack Thrombospondin 2 Display Connective Tissue Abnormalities That Are Associated with Disordered Collagen Fibrillogenesis, an Increased Vascular Density, and a Bleeding Diathesis," <i>J. Cell Biol.</i> , 140(2):419-430 (1998).			
	AS2	Yang, Z., et al., "Matricellular Proteins as Modulators of Cell-Matrix Interactions: Adhesive Defect in Thrombospondin 2-null Fibroblasts in a Consequence of Increased Levels of Matrix Metalloproteinase-2," <i>Mol. Biol. Cell</i> , 11(10):3353-3364 (2000).			
	AT2	Lawler, J., et al., "Characterization of Human Thrombospondin-4*," <i>J. Biol. Chem.</i> , 270(6): 2809-2814 (1995).			
EXAMINER		DATE CONSIDERED			